

catalogs or other public documents during the normal course of business. The nominal amount of burden imposed on the public is simply to relay the requested information.

*Respondents:* 14,000.

*Responses per Respondent:* 1.

*Total Annual Responses:* 14,000.

*Hours per Response:* 0.03 (2 minutes).

*Total Burden Hours:* 420.

### C. Public Comments

Public comments are particularly invited on: Whether this collection of information is necessary and whether it will have practical utility; whether our estimate of the public burden of this collection of information is accurate and based on valid assumptions and methodology; and ways to enhance the quality, utility, and clarity of the information to be collected.

Obtaining Copies of Proposals: Requesters may obtain a copy of the information collection documents from the Regulatory Secretariat Division, at [GSARegSec@gsa.gov](mailto:GSARegSec@gsa.gov).

Please cite OMB Control No. 3090–0250, FSS Contract Administration Information, in all correspondence.

**Jeffrey A. Koses,**

*Senior Procurement Executive, Office of Acquisition Policy, Office of Government-wide Policy.*

[FR Doc. 2023–24433 Filed 11–3–23; 8:45 am]

**BILLING CODE 6820–14–P**

## GENERAL SERVICES ADMINISTRATION

[Notice-MRB–2023–06; Docket No. 2023–0002; Sequence No. 37]

### GSA Acquisition Policy Federal Advisory Committee; Notification of Upcoming Web-Based Public Meeting

**AGENCY:** Office of Government-wide Policy (OGP), General Services Administration (GSA).

**ACTION:** Meeting notice.

**SUMMARY:** GSA is providing notice of a meeting of the GSA Acquisition Policy Federal Advisory Committee (hereinafter “the Committee” or “the GAP FAC”) in accordance with the requirements of the Federal Advisory Committee Act (FACA). This meeting will be open to the public, accessible via webcast. Information on attending and providing written public comment is under the **SUPPLEMENTARY INFORMATION** section.

**DATES:** The GAP FAC will hold an open public meeting on Tuesday, December 5, 2023, from 1 p.m. to 4:30 p.m. eastern standard time (EST).

**ADDRESSES:** The meeting will be accessible via webcast. Registrants will receive the webcast information before the meeting.

#### FOR FURTHER INFORMATION CONTACT:

Boris Arratia, Designated Federal Officer, OGP, 703–795–0816, or email: [boris.arratia@gsa.gov](mailto:boris.arratia@gsa.gov); or Stephanie Hardison, OGP, 202–258–6823, or email: [stephanie.hardison@gsa.gov](mailto:stephanie.hardison@gsa.gov). Additional information about the Committee, including meeting materials and agendas, are available on-line at <https://gsa.gov/policy-regulations/policy/acquisition-policy/gsa-acquisition-policy-federal-advisory-committee>.

#### SUPPLEMENTARY INFORMATION:

##### Purpose of the Meeting

The purpose of this meeting is for each of the three subcommittees (Policy and Practice, Industry Partnerships, and Acquisition Workforce) to present recommendations to the full Committee. The Committee will, in turn, deliberate and vote on GAP FAC recommendations to be delivered to the GSA Administrator.

##### Meeting Agenda

- Opening Remarks
- Guest Speaker
- Acquisition Workforce Subcommittee Recommendations and Discussion
- Vote on recommendations
- Industry Partnerships Subcommittee Recommendations and Discussion
- Vote on recommendations
- Policy and Practices Subcommittee Recommendations and Discussion
- Vote on recommendations
- Closing Remarks and Adjourn

##### Meeting Registration

This meeting is open to the public and will be accessible by webcast. Registration information is located on the GAP FAC website: <https://www.gsa.gov/policy-regulations/policy/acquisition-policy/gsa-acquisition-policy-federal-advisory-committee>. Public attendees who want to attend virtually will need to register no later than 5 p.m. EST, on Monday, December 4, 2023 to obtain the meeting webcast information. All registrants will be asked to provide their name, affiliation, and email address. After registration, individuals will receive webcast access information details via email.

Public Comments:

Written public comments are being accepted via email at [gapfac@gsa.gov](mailto:gapfac@gsa.gov). To submit a written public comment, please email at [gapfac.gsa.gov](mailto:gapfac.gsa.gov) and

include your name, organization name (if applicable).

**Jeffrey A. Koses,**

*Senior Procurement Executive, Office of Acquisition Policy, Office of Government-wide Policy.*

[FR Doc. 2023–24432 Filed 11–3–23; 8:45 am]

**BILLING CODE 6820–RV–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA–2023–P–2536]

#### Determination That FORADIL (Formoterol Fumarate) Inhalation Powder, 0.012 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA, the Agency, or we) has determined that FORADIL (formoterol fumarate) inhalation powder, 0.012 milligrams (mg)/inhalation (inh), was not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to approve abbreviated new drug applications (ANDAs) for formoterol fumarate inhalation powder, 0.012 mg/inh, if all other legal and regulatory requirements are met.

**FOR FURTHER INFORMATION CONTACT:** Joe Thomas, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6217, Silver Spring, MD 20993–0002, 202–815–5571, [joseph.thomas1@fda.hhs.gov](mailto:joseph.thomas1@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of an ANDA to market a generic version of a previously approved drug product. To obtain approval, the ANDA applicant must show, among other things, that the generic drug product: (1) has the same active ingredient(s), dosage form, route of administration, strength, conditions of use, and (with certain exceptions) labeling as the listed drug, which is a version of the drug that was previously approved; and (2) is bioequivalent to the listed drug. ANDA applicants do not have to repeat the extensive clinical testing otherwise necessary to gain approval of a new drug application (NDA).

Section 505(j)(7) of the FD&C Act requires FDA to publish a list of all